Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation

• DOI: 10.1016/j.crtox.2024.100194
• Publication Date: 2024-09-23T15:27:08Z
• Authors: Chunhong Chu; Huixia Xu; Chenxue Liu; Xiangkai Wei; Lanxin Li; Rui Wang; Wenrui Cui; Guoliang Zhang; Chenyang Liu; Ke Wang; Lei An; Fei He
• Keywords: RA1190-1270; L861Q; Mutation; Proliferation; Cytotoxicology; Toxicology. Poisons; CUDC-101; Research Paper

The epidermal growth factor receptor (EGFR) represents an effective target for the treatment of non-small cell lung cancer. In classical EGFR mutations, tyrosine kinase inhibitors have achieved desirable clinical efficacy. However, effectiveness (TKIs) against L861Q mutation has not been fully established. this study, four lines containing were constructed by CRISPR and anti-tumour effects CUDC-101 on them investigated in vitro various chemosensitivity methods, with afatinib serving as a positive control. results demonstrated that inhibited proliferation clonogenic capacity cells through ERK or AKT pathways, decreased mitochondrial membrane potential cells, blocked cycle promoted apoptosis. Our findings suggest may be promising option NSCLC patients exon 18 substitution L861Q.